Close Menu

Waters

The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.

The investment bank said the recent pullback in the company's stock has made its valuation more attractive. 

Research centers in six countries will work on metabolome-related global health challenges including autism, cancer, diabetes, dementia, and obesity.

In addition to Illumina and Thermo Fisher, the investment bank reinitiated coverage of Bruker, Invitae, Agilent, Waters, and T2 Biosystems.

Posting strong pharma sales but weakness in academia and government, Waters matched analysts' average EPS estimate for the quarter but fell short on revenues.

Among the launches at the organization's annual meeting this week in Taipei were a personalized proteomics initiative and a new DIA mass spec method.

The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.

The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.

While most firms launched new mass spec systems, the larger focus was on developing and implementing the larger workflows surrounding these instruments.

Along with scientists from the University of Leicester, the researchers picked the Xevo TQ-S micro platform to do a pilot study on heart failure patient samples.

Pages

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.